Search
Rigel Pharmaceuticals Inc
RIGLAdd to Watchlist
38.720USD
+0.430+1.12%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
716.40MMarket Cap
1.91P/E TTM
More Details of Rigel Pharmaceuticals Inc Company
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Rigel Pharmaceuticals Inc Info
Ticker SymbolRIGL
Company nameRigel Pharmaceuticals Inc
IPO dateNov 29, 2000
CEORodriguez (Raul R)
Number of employees162
Security typeOrdinary Share
Fiscal year-endNov 29
Address- -
City- -
Stock exchangeNASDAQ OMX - NASDAQ BASIC
Country- -
Postal code- -
Phone- -
Website- -
Ticker SymbolRIGL
IPO dateNov 29, 2000
CEORodriguez (Raul R)
Company Executives of Rigel Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
279.59K
-0.87%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
78.79K
+3.11%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
62.00K
-1.41%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
34.00K
-2.50%
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
18.47K
+31.13%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
18.25K
+31.51%
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
10.13K
-24.69%
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alison L. Hannah, M.D.
Dr. Alison L. Hannah, M.D.
Independent Director
Independent Director
--
--
Mr. Raymond J. Furey
Mr. Raymond J. Furey
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
279.59K
-0.87%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
78.79K
+3.11%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
62.00K
-1.41%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
34.00K
-2.50%
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
18.47K
+31.13%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
18.25K
+31.51%
FAQs
Who are the top five shareholders of Rigel Pharmaceuticals Inc?
The top five shareholders of Rigel Pharmaceuticals Inc are: Mr. Raul R. Rodriguez
How many institutions hold shares of Rigel Pharmaceuticals Inc (RIGL)?
As of 2026Q1, 365 institutions hold shares of Rigel Pharmaceuticals Inc, with a combined market value of approximately 17.75M, accounting for 95.95% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 784716.00.